Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Profile

Martin Cannon

Concepts (299)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Dendritic Cells
26
2023
133
3.740
 Why?
Ovarian Neoplasms
23
2023
450
3.720
 Why?
Cancer Vaccines
13
2020
78
3.000
 Why?
Immunotherapy
12
2019
235
1.930
 Why?
Th17 Cells
3
2020
25
1.500
 Why?
Antigens, Neoplasm
11
2019
146
1.330
 Why?
CD4-Positive T-Lymphocytes
8
2023
157
1.070
 Why?
Uterine Cervical Neoplasms
13
2011
278
0.960
 Why?
Oncogene Proteins, Viral
7
2011
52
0.810
 Why?
Neoplasm Recurrence, Local
3
2020
634
0.760
 Why?
T-Lymphocytes, Regulatory
6
2011
82
0.730
 Why?
T-Lymphocytes, Cytotoxic
12
2013
64
0.710
 Why?
Indoleamine-Pyrrole 2,3,-Dioxygenase
3
2014
16
0.660
 Why?
Lymphocytes, Tumor-Infiltrating
4
2019
75
0.610
 Why?
Neoplasms
4
2019
1237
0.570
 Why?
CD8-Positive T-Lymphocytes
11
2023
123
0.560
 Why?
Antibodies, Monoclonal
5
2019
462
0.560
 Why?
DNA-Binding Proteins
5
2007
424
0.540
 Why?
Interleukin-17
2
2020
37
0.540
 Why?
p38 Mitogen-Activated Protein Kinases
2
2014
96
0.520
 Why?
Ascites
1
2014
29
0.450
 Why?
T-Lymphocytes
5
2017
331
0.450
 Why?
Immunologic Surveillance
2
2011
10
0.440
 Why?
Female
42
2023
26981
0.410
 Why?
Cytokines
4
2014
606
0.400
 Why?
Signal Transduction
3
2017
1625
0.400
 Why?
Carcinoma
2
2017
139
0.400
 Why?
T-Lymphocytes, Helper-Inducer
2
2011
42
0.380
 Why?
Immunotherapy, Active
1
2011
4
0.380
 Why?
Serine Endopeptidases
3
2009
51
0.370
 Why?
Cytotoxicity, Immunologic
7
2011
56
0.370
 Why?
Humans
53
2023
50389
0.360
 Why?
Adoptive Transfer
1
2009
30
0.330
 Why?
Immunotherapy, Adoptive
3
2005
162
0.320
 Why?
Interferon-gamma
7
2020
176
0.310
 Why?
Epitopes, T-Lymphocyte
3
2008
25
0.300
 Why?
Lymphocyte Activation
3
2005
172
0.280
 Why?
Adjuvants, Immunologic
3
2011
51
0.270
 Why?
Papillomavirus Vaccines
1
2007
67
0.270
 Why?
Herpesvirus 4, Human
2
2005
39
0.270
 Why?
Immunodominant Epitopes
2
2008
8
0.270
 Why?
Cell Line, Tumor
13
2022
1399
0.260
 Why?
Animals
16
2023
13173
0.260
 Why?
Dependovirus
3
2011
102
0.240
 Why?
HLA-A2 Antigen
3
2009
11
0.220
 Why?
Cell Transformation, Viral
1
2003
25
0.210
 Why?
Cell Line, Transformed
1
2003
73
0.210
 Why?
Poxviridae Infections
1
2022
4
0.210
 Why?
Poxviridae
1
2022
7
0.210
 Why?
Oncolytic Virotherapy
1
2022
18
0.210
 Why?
Myxoma virus
1
2022
14
0.210
 Why?
Interferon Type I
1
2022
24
0.200
 Why?
Cystadenocarcinoma, Serous
5
2009
71
0.200
 Why?
Vaccination
4
2010
275
0.200
 Why?
Receptor, erbB-2
4
2008
75
0.190
 Why?
Papillomavirus E7 Proteins
5
2011
31
0.190
 Why?
Disease-Free Survival
2
2020
450
0.190
 Why?
Interleukin-10
2
2017
84
0.190
 Why?
Genes, MHC Class I
3
2008
11
0.190
 Why?
Testis
2
2011
65
0.180
 Why?
Membrane Proteins
4
2011
348
0.180
 Why?
Injections, Intradermal
1
2020
14
0.180
 Why?
Macrophages
4
2022
363
0.180
 Why?
Immunity, Humoral
1
2020
22
0.180
 Why?
Coculture Techniques
3
2014
143
0.180
 Why?
Flow Cytometry
8
2013
475
0.170
 Why?
Folate Receptor 1
1
2020
25
0.170
 Why?
Cell Movement
2
2019
246
0.170
 Why?
Enzyme-Linked Immunosorbent Assay
2
2013
234
0.170
 Why?
Carcinoma, Hepatocellular
1
2022
196
0.170
 Why?
Mice
9
2023
5688
0.170
 Why?
Carcinoma, Lewis Lung
1
2019
9
0.170
 Why?
B-Lymphocytes
5
2017
175
0.170
 Why?
Repressor Proteins
3
2011
149
0.160
 Why?
Melanoma, Experimental
1
2019
40
0.160
 Why?
Self Tolerance
1
2019
1
0.160
 Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2019
1
0.160
 Why?
Liver Neoplasms
1
2022
331
0.160
 Why?
Aged
12
2020
9590
0.160
 Why?
Transplantation, Autologous
1
2020
464
0.160
 Why?
Cells, Cultured
6
2014
1589
0.150
 Why?
Cytotoxicity Tests, Immunologic
4
2005
27
0.150
 Why?
N-Acetylglucosaminyltransferases
1
2017
16
0.140
 Why?
Programmed Cell Death 1 Receptor
1
2017
40
0.140
 Why?
Middle Aged
16
2020
12460
0.140
 Why?
HLA Antigens
4
2006
53
0.140
 Why?
Receptors, Notch
1
2017
27
0.140
 Why?
Human Umbilical Vein Endothelial Cells
2
2014
90
0.140
 Why?
Neoplastic Stem Cells
1
2017
100
0.130
 Why?
Carcinoma, Papillary
3
2005
49
0.130
 Why?
Poliovirus Vaccine, Oral
2
2005
4
0.120
 Why?
Adult
15
2011
13568
0.120
 Why?
Genetic Vectors
3
2011
127
0.120
 Why?
Poliovirus
2
2005
10
0.120
 Why?
Neoplasm Proteins
1
2017
321
0.120
 Why?
Clinical Trials, Phase I as Topic
1
2015
24
0.120
 Why?
Adenocarcinoma
3
2004
402
0.120
 Why?
Antigen Presentation
5
2009
25
0.120
 Why?
Galectin 3
1
2014
14
0.120
 Why?
Kallikreins
2
2005
18
0.120
 Why?
Neoplasm Invasiveness
3
2017
269
0.120
 Why?
Cystadenocarcinoma, Papillary
2
2005
14
0.110
 Why?
Histocompatibility Antigens Class I
2
2005
44
0.110
 Why?
Peptide Fragments
4
2009
207
0.110
 Why?
Endometrial Neoplasms
2
2005
137
0.110
 Why?
Uterine Neoplasms
2
2005
60
0.110
 Why?
Papillomavirus Infections
3
2011
168
0.110
 Why?
Mutation
1
2019
1292
0.100
 Why?
Mice, Inbred C57BL
3
2017
1785
0.100
 Why?
Intracellular Signaling Peptides and Proteins
2
2022
139
0.100
 Why?
Lymphocytes
1
2013
154
0.100
 Why?
Killer Cells, Natural
4
2005
106
0.100
 Why?
Antigens, Viral
3
2007
43
0.100
 Why?
V-Set Domain-Containing T-Cell Activation Inhibitor 1
1
2011
4
0.100
 Why?
rho GTP-Binding Proteins
1
2011
6
0.100
 Why?
Clonal Anergy
1
2011
13
0.090
 Why?
A Kinase Anchor Proteins
1
2011
2
0.090
 Why?
Calmodulin-Binding Proteins
1
2011
10
0.090
 Why?
Drug Resistance, Neoplasm
5
2017
318
0.090
 Why?
Antigen-Presenting Cells
1
2011
24
0.090
 Why?
Antigens, Surface
1
2011
48
0.090
 Why?
Human papillomavirus 16
1
2011
44
0.090
 Why?
Antineoplastic Agents, Alkylating
1
2011
74
0.090
 Why?
Uterine Cervical Dysplasia
1
2011
49
0.090
 Why?
Immunity, Cellular
2
2008
69
0.090
 Why?
Cyclophosphamide
1
2011
164
0.090
 Why?
Prostate
1
2011
117
0.090
 Why?
Diphosphonates
1
2011
90
0.090
 Why?
Imidazoles
1
2011
128
0.090
 Why?
Phenotype
1
2013
736
0.090
 Why?
Gene Expression Regulation, Neoplastic
4
2011
830
0.080
 Why?
Gene Expression Profiling
2
2005
1029
0.080
 Why?
Papillomaviridae
3
2005
103
0.080
 Why?
Neoplasm Staging
3
2007
750
0.080
 Why?
K562 Cells
2
2008
41
0.080
 Why?
Carrier Proteins
1
2011
302
0.080
 Why?
Tumor Microenvironment
2
2023
223
0.080
 Why?
CA-125 Antigen
1
2008
17
0.080
 Why?
Immediate-Early Proteins
1
2008
19
0.080
 Why?
Cytomegalovirus
1
2008
27
0.080
 Why?
RNA, Messenger
4
2005
1101
0.080
 Why?
Green Fluorescent Proteins
1
2008
92
0.080
 Why?
Interleukin-4
2
2005
44
0.070
 Why?
Antibody Formation
1
2007
51
0.070
 Why?
Antibodies, Viral
1
2007
92
0.070
 Why?
Prostatic Neoplasms
1
2011
394
0.070
 Why?
Amino Acid Sequence
2
2005
579
0.070
 Why?
RNA Interference
2
2017
178
0.070
 Why?
Ovary
3
2017
114
0.070
 Why?
Molecular Sequence Data
2
2005
799
0.070
 Why?
Oligonucleotide Array Sequence Analysis
2
2005
409
0.070
 Why?
Recombinant Proteins
1
2007
482
0.070
 Why?
Hypersensitivity, Delayed
1
2005
19
0.060
 Why?
Breast Neoplasms
3
2003
1189
0.060
 Why?
Neoplasms, Squamous Cell
1
2005
7
0.060
 Why?
Monocytes
2
2022
131
0.060
 Why?
Cell Line
4
2010
1010
0.060
 Why?
Electroporation
1
2005
18
0.060
 Why?
Poliomyelitis
1
2005
5
0.060
 Why?
Enterotoxins
1
2005
12
0.060
 Why?
Gene Transfer Techniques
1
2005
39
0.060
 Why?
Genes, erbB-2
1
2005
8
0.060
 Why?
Interleukin-12
1
2005
29
0.060
 Why?
Immunologic Memory
1
2005
29
0.060
 Why?
Reverse Transcriptase Polymerase Chain Reaction
4
2008
578
0.060
 Why?
Antigens, Heterophile
1
2005
1
0.060
 Why?
Plasmodium falciparum
1
2005
19
0.060
 Why?
Burkitt Lymphoma
1
2005
26
0.060
 Why?
Malaria, Falciparum
1
2005
14
0.060
 Why?
Endemic Diseases
1
2005
22
0.060
 Why?
Epstein-Barr Virus Infections
1
2005
29
0.060
 Why?
Gangliosides
1
2004
5
0.060
 Why?
Ascitic Fluid
1
2004
12
0.060
 Why?
Proteins
2
2005
350
0.060
 Why?
Genetic Therapy
1
2005
118
0.060
 Why?
Ovariectomy
1
2004
113
0.060
 Why?
Vaccines, Subunit
1
2004
15
0.060
 Why?
Hysterectomy
1
2004
88
0.060
 Why?
Immunization, Passive
1
2004
28
0.060
 Why?
Clinical Trials as Topic
2
2007
465
0.060
 Why?
Interleukin-6
1
2005
266
0.060
 Why?
Tumor Necrosis Factor-alpha
2
2019
388
0.060
 Why?
Cell Differentiation
2
2004
651
0.050
 Why?
Protein Binding
1
2005
657
0.050
 Why?
Epithelial Cells
1
2005
210
0.050
 Why?
Vesiculovirus
1
2022
6
0.050
 Why?
Virus Latency
1
2003
51
0.050
 Why?
Vaccinia virus
1
2022
6
0.050
 Why?
Host Specificity
1
2022
5
0.050
 Why?
Cell Adhesion Molecules
1
2003
87
0.050
 Why?
Cell Communication
1
2003
69
0.050
 Why?
Nucleotidyltransferases
1
2022
13
0.050
 Why?
Mammals
1
2022
57
0.050
 Why?
Disease Models, Animal
2
2022
1419
0.050
 Why?
Tumor Cells, Cultured
4
2003
462
0.050
 Why?
Xenograft Model Antitumor Assays
2
2017
213
0.050
 Why?
Disease Progression
2
2019
823
0.050
 Why?
Radiotherapy
1
2002
124
0.050
 Why?
Rabbits
1
2022
375
0.050
 Why?
Down-Regulation
1
2003
343
0.050
 Why?
Blood Transfusion
1
2002
127
0.050
 Why?
Viral Proteins
1
2022
156
0.050
 Why?
Immunohistochemistry
4
2005
975
0.040
 Why?
Carcinoma, Squamous Cell
1
2004
325
0.040
 Why?
Transcriptome
1
2022
316
0.040
 Why?
Endothelium
1
2019
37
0.040
 Why?
Intercellular Adhesion Molecule-1
1
2019
61
0.040
 Why?
Gene Expression
3
2008
613
0.040
 Why?
Antineoplastic Combined Chemotherapy Protocols
1
2004
1003
0.040
 Why?
Injections, Intraperitoneal
2
2010
57
0.040
 Why?
Tissue Banks
1
2017
8
0.040
 Why?
Antibodies, Monoclonal, Humanized
3
2004
224
0.040
 Why?
Mice, Inbred NOD
1
2017
94
0.040
 Why?
STAT3 Transcription Factor
1
2017
80
0.040
 Why?
Glycosylation
1
2017
102
0.040
 Why?
Tumor Burden
1
2017
131
0.030
 Why?
RNA, Small Interfering
1
2017
210
0.030
 Why?
Multiple Myeloma
1
2011
2949
0.030
 Why?
Protein Processing, Post-Translational
1
2017
154
0.030
 Why?
Lung Neoplasms
1
2002
600
0.030
 Why?
Kaplan-Meier Estimate
1
2017
466
0.030
 Why?
Survival Analysis
2
2010
671
0.030
 Why?
Apoptosis
2
2014
1094
0.030
 Why?
Pore Forming Cytotoxic Proteins
2
2005
9
0.030
 Why?
Perforin
2
2005
11
0.030
 Why?
Anti-Bacterial Agents
1
2019
745
0.030
 Why?
Neovascularization, Pathologic
1
2014
153
0.030
 Why?
Interleukin-2
2
2003
70
0.030
 Why?
Membrane Glycoproteins
2
2005
244
0.030
 Why?
Vaginal Smears
1
2011
28
0.020
 Why?
Organ Specificity
1
2011
109
0.020
 Why?
Prostate-Specific Antigen
1
2011
47
0.020
 Why?
DNA, Viral
1
2011
133
0.020
 Why?
Time Factors
2
2010
2934
0.020
 Why?
Major Histocompatibility Complex
1
2010
12
0.020
 Why?
Prognosis
2
2005
1979
0.020
 Why?
Transduction, Genetic
1
2008
45
0.020
 Why?
Fluorescent Antibody Technique
1
2008
112
0.020
 Why?
Leukocytes, Mononuclear
1
2008
113
0.020
 Why?
Alphapapillomavirus
1
2007
13
0.020
 Why?
T-Lymphocyte Subsets
1
2007
38
0.020
 Why?
Models, Immunological
1
2007
8
0.020
 Why?
Aged, 80 and over
2
2005
3180
0.020
 Why?
Immune Tolerance
1
2007
84
0.020
 Why?
Adolescent
2
2011
6475
0.020
 Why?
HLA-B Antigens
1
2006
7
0.020
 Why?
Clone Cells
1
2006
78
0.020
 Why?
Immunity, Innate
1
2007
105
0.020
 Why?
Male
3
2011
25718
0.020
 Why?
Claudin-3
1
2005
5
0.020
 Why?
Claudin-4
1
2005
7
0.020
 Why?
Combined Modality Therapy
1
2007
641
0.020
 Why?
Mice, Inbred C3H
1
2005
84
0.020
 Why?
Peptides
1
2006
221
0.020
 Why?
Protein Sorting Signals
1
2005
10
0.020
 Why?
Protein Engineering
1
2005
18
0.020
 Why?
Histocompatibility Antigens Class II
1
2005
37
0.010
 Why?
Mice, SCID
1
2005
173
0.010
 Why?
Species Specificity
1
2005
192
0.010
 Why?
Plasmids
1
2005
164
0.010
 Why?
Protein Folding
1
2005
48
0.010
 Why?
Epithelium
1
2004
65
0.010
 Why?
Endocytosis
1
2005
61
0.010
 Why?
Carboplatin
1
2004
51
0.010
 Why?
Receptors, Cell Surface
1
2005
120
0.010
 Why?
Radiotherapy, Adjuvant
1
2004
60
0.010
 Why?
Paclitaxel
1
2004
83
0.010
 Why?
Transfection
1
2005
354
0.010
 Why?
Antineoplastic Agents, Hormonal
1
2004
49
0.010
 Why?
Polymerase Chain Reaction
1
2005
456
0.010
 Why?
Antibody-Dependent Cell Cytotoxicity
1
2003
12
0.010
 Why?
Tumor Stem Cell Assay
1
2003
17
0.010
 Why?
Proportional Hazards Models
1
2005
418
0.010
 Why?
Cervix Uteri
1
2004
48
0.010
 Why?
Up-Regulation
1
2005
449
0.010
 Why?
Swine
1
2005
408
0.010
 Why?
Kinetics
1
2005
635
0.010
 Why?
Keratinocytes
1
2004
91
0.010
 Why?
Receptors, Interleukin-2
1
2002
7
0.010
 Why?
Lymphocyte Subsets
1
2002
13
0.010
 Why?
Receptors, Antigen, T-Cell
1
2003
49
0.010
 Why?
Cell Culture Techniques
1
2003
97
0.010
 Why?
Antigens, CD19
1
2002
27
0.010
 Why?
Receptors, IgG
1
2002
22
0.010
 Why?
Leukocytes
1
2003
69
0.010
 Why?
Cell Death
1
2003
174
0.010
 Why?
Doxorubicin
1
2004
234
0.010
 Why?
Immunophenotyping
1
2002
111
0.010
 Why?
Cisplatin
1
2004
275
0.010
 Why?
Survival Rate
1
2005
915
0.010
 Why?
Tumor Virus Infections
1
2002
46
0.010
 Why?
Antibodies, Monoclonal, Murine-Derived
1
2002
47
0.010
 Why?
Young Adult
1
2011
4064
0.010
 Why?
Fatal Outcome
1
2002
195
0.010
 Why?
Cell Division
1
2002
294
0.010
 Why?
Case-Control Studies
1
2004
1148
0.010
 Why?
Prospective Studies
1
2004
2414
0.010
 Why?
Risk Factors
1
2004
3692
0.010
 Why?
Antineoplastic Agents
1
2002
1178
0.010
 Why?
Cannon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (299) concept(s)
_
Co-Authors Expand Description
See all (18) people
_
Similar People Expand Description
See all (34) people
_
Same Department Expand Description
Search Department